Company intelligence / Profile preview

CD4 Therapeutics

Munich, Bavaria, Germanycd4therapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CD4 Therapeutics is developing tregalizumab, a first-in-class monoclonal antibody designed to selectively activate regulatory T-cells (Tregs) for the treatment of autoimmune and inflammatory diseases. The company holds rights to develop tregalizumab, which previously demonstrated clinical proof-of-concept in prioritized indications. Sum of clinical evidence supports continued development in focused autoimmune indications, with anticipated expansion to broader autoimmune markets[1][4].

Therapeutic areas: DermatologyImmunologyGastroenterology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

tregalizumab

Partnerships

T-Balance Therapeutics

Beyond the preview

Go deeper on CD4 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD4 Therapeutics.

Explore the full profile